---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-102795"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-08-28T12:30:17+00:00"
generated_at: "2026-08-28T12:35:32.037030+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aprea expands IP portfolio to 28 issued, 30 pending patents for oncology programs

## Summary
- Total portfolio now 28 issued and 30 pending patents across WEE1 and ATR inhibitor programs.
- WEE1 program: 2 pending US apps, 1 provisional, 2 granted non-US patents (Australia, Korea), 12 pending non-US; expiry 2047.
- ATR program: 4 granted US patents, 22 granted non-US, 13 pending non-US; granted expire 2035-2037, pending could extend to 2045.
- Lead WEE1 inhibitor APR-1051 in ACESOT-1051 Phase 1 trial for advanced solid tumors with gene alterations.
- ATRN-119 RP2D set at 1,100 mg once daily in 2025; study closed to focus on APR-1051, combo approaches considered.

## SEC filing metadata
- accession: 0001104659-26-102795
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-08-28T12:30:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/0001104659-26-102795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/apre-20260828x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-102795
- JSON: https://secwatch.observer/filing/0001104659-26-102795.json
- Plain text: https://secwatch.observer/filing/0001104659-26-102795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.